Evidence map›Paper›PMID 41497346›Full record

ArticleJournal of translational autoimmunity2026

Autoantibodies reactive with glomerular endothelial cells and podocytes in patients with membranous nephropathy.

Vojtech Petr, Shrey Purohit, Felix Poppelaars, Brandon Renner, Jennifer Laskowski, Russell Whelan, Liudmila Kulik, Jessica Kendrick, Ashley Frazer-Abel, Diana Jalal and 7 more

Abstract read
In one paragraph

Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Vojtech PetrInstitute for Clinical and Experimental Medicine, Prague, Czech Republic.
Shrey PurohitDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Felix PoppelaarsDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Brandon RennerDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Jennifer LaskowskiDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Russell WhelanDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Liudmila KulikDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Jessica KendrickDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Ashley Frazer-AbelExsera BioLabs, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Diana JalalDepartment of Medicine, Carver College of Medicine, University of Iowa, IA, USA.
Barbara MarcolinDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Isabelle SchmelzerDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.
Hanna DebiecDepartment of Nephrology and Dialysis, Sorbonne University, Paris, France.
Pierre RoncoDepartment of Nephrology and Dialysis, Sorbonne University, Paris, France.
Moin A SaleemDepartment of Pediatric Nephrology, Bristol Renal and Royal Bristol Children Hospital, University of Bristol, Bristol, UK.
Simon C SatchellBristol Renal, University of Bristol, Bristol, UK.
Joshua M ThurmanDepartment of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.

Funding

The Complement System and Ischemic Acute Renal FailureR01DK076690 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Joshua M Thurman · 2008 to 2026
$6.6M
NIDDK NIH HHS R01 DK076690
6 · The paper itself

Abstract

Rationale & objective: Membranous nephropathy (MN) is a glomerular disease caused by autoantibodies reactive with podocyte antigens. The most common antigen is the M-type phospholipase A2 receptor (PLA2R), but autoantibodies to other podocyte antigens have also been identified. Investigators have reported elevated levels of complement fragments in plasma. However, most complement fragments generated on podocytes are likely to pass into the urine and not enter the bloodstream. Further, anti-PLA2R antibodies are usually IgG4 subclass and do not activate the classical pathway of complement. To look for additional autoantibodies capable of generating endovascular complement fragments, we examined whether MN patients have antibodies reactive with endothelial cell antigens. Study design: Retrospective cohort study. Setting & participants: We analyzed plasma samples from 64 patients with MN, and results were compared to healthy controls and patients with chronic kidney disease. Exposure: Plasma and urine complement activation fragments, glomerular endothelial cell and podocyte antibody binding assays, anti-cardiolipin antibody enzyme linked immunosorbent assay. Outcome: Proteinuria, estimated glomerular filtration rate. Analytical approach: Groups were compared with Wilcoxon, Kruskal-Wallis or chi-square tests. Correlations were performed using Pearson's correlation. Results: Plasma C3a, C4a, C5a, and sC5b-9 levels were elevated in MN patients. Some patients had IgG reacted with glomerular endothelial cells or with podocytes. These antibodies were seen in distinct subsets of patients and did not correlate with the presence of anti-PLA2R antibodies. Higher titers of anti-glomerular endothelial cell antibodies correlated with systemic complement activation, seen by sC5b-9, and disease severity, determined by proteinuria. Anti-cardiolipin IgG levels associated with proteinuria. Limitations: Assays used immortalized cell lines, and target antigens have not yet been identified. Conclusions: MN is a disease of autoimmunity directed against podocyte antigens, but some patients may also produce autoantibodies that target antigens on glomerular endothelial cells. The level of these antibodies correlates with adverse clinical findings.

Indexed as

AutoantibodyComplementGlomerular endothelial cellsMembranous nephropathy

Identifiers

PMID41497346
PMCPMC12767797

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.